Ultimovacs ASA (ULTI.OL)

NOK 2.05

(0.0%)

Net Income Summary of Ultimovacs ASA

Ultimovacs ASA's latest annual net income in 2023 was -189.23 Million NOK , down -28.82% from previous year.
Ultimovacs ASA's latest quarterly net income in 2024 Q2 was -44.76 Million NOK , down -96.76% from previous quarter.
Ultimovacs ASA reported an annual net income of -146.9 Million NOK in 2022, up 11.91% from previous year.
Ultimovacs ASA reported an annual net income of -166.75 Million NOK in 2021, down -42.87% from previous year.
Ultimovacs ASA reported a quarterly net income of -44.76 Million NOK for 2024 Q2, down -96.76% from previous quarter.
Ultimovacs ASA reported a quarterly net income of -17.45 Million NOK for 2023 Q1, up 67.31% from previous quarter.

Annual Net Income Chart of Ultimovacs ASA (2023 - 2016)

Historical Annual Net Income of Ultimovacs ASA (2023 - 2016)

Year	Net Income	Net Income Growth
2023	-189.23 Million NOK	-28.82%
2022	-146.9 Million NOK	11.91%
2021	-166.75 Million NOK	-42.87%
2020	-116.71 Million NOK	-108.98%
2019	-55.85 Million NOK	-3.61%
2018	-53.9 Million NOK	-67.05%
2017	-32.26 Million NOK	-12.14%
2016	-28.77 Million NOK	0.0%

Year	Net Income	Net Income Growth
2024 Q1	-22.75 Million NOK	59.32%
2024 Q2	-44.76 Million NOK	-96.76%
2023 Q1	-17.45 Million NOK	67.31%
2023 Q4	-55.93 Million NOK	-0.2%
2023 Q3	-55.82 Million NOK	-28.7%
2023 Q2	-43.37 Million NOK	-148.44%
2023 FY	-189.23 Million NOK	-28.82%
2022 Q2	-9.33 Million NOK	77.41%
2022 Q1	-41.3 Million NOK	20.13%
2022 FY	-146.9 Million NOK	11.91%
2022 Q4	-53.41 Million NOK	-64.08%
2022 Q3	-32.55 Million NOK	-248.85%
2021 Q1	-36.38 Million NOK	-75.36%
2021 FY	-166.75 Million NOK	-42.87%
2021 Q4	-51.7 Million NOK	-17.26%
2021 Q2	-33.75 Million NOK	7.21%
2021 Q3	-44.09 Million NOK	-30.63%
2020 Q4	-20.74 Million NOK	31.6%
2020 Q1	-29.41 Million NOK	-46.72%
2020 Q2	-33.63 Million NOK	-14.35%
2020 Q3	-30.33 Million NOK	9.81%
2020 FY	-116.71 Million NOK	-108.98%
2019 Q1	-14.47 Million NOK	-27.89%
2019 FY	-55.85 Million NOK	-3.61%
2019 Q4	-20.04 Million NOK	-32.3%
2019 Q3	-15.15 Million NOK	-321.85%
2019 Q2	-3.59 Million NOK	75.19%
2018 Q1	-10.87 Million NOK	-53.91%
2018 FY	-53.9 Million NOK	-67.05%
2018 Q4	-11.31 Million NOK	31.88%
2018 Q3	-16.61 Million NOK	-13.64%
2018 Q2	-14.62 Million NOK	-34.5%
2017 Q1	-8.81 Million NOK	0.0%
2017 Q2	-7.72 Million NOK	12.33%
2017 Q4	-7.06 Million NOK	15.52%
2017 Q3	-8.36 Million NOK	-8.18%
2017 FY	-32.26 Million NOK	-12.14%
2016 FY	-28.77 Million NOK	0.0%

Peer Net Income Comparison of Ultimovacs ASA

Name	Net Income	Net Income Difference
Arctic Bioscience AS	-45.51 Million NOK	-315.776%
Aqua Bio Technology ASA	-19.11 Million NOK	-890.118%
ArcticZymes Technologies ASA	19.42 Million NOK	1074.203%
BerGenBio ASA	-190.4 Million NOK	0.61%
Hofseth BioCare ASA	-106.68 Million NOK	-77.384%
PCI Biotech Holding ASA	-20.31 Million NOK	-831.524%
Thor Medical ASA	-26.56 Million NOK	-612.469%